J&J Partners with India's IMTECH to Develop New Treatments for TB

02:06 EDT 17 Aug 2017 | Genetic Engineering News

Johnson & Johnson (J&J) scientists are partnering with researchers at India’s Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to discover and develop new treatments for tuberculosis (TB). The two organizations have inked a Memorandum of Understanding, under which J&J’s global public heath team scientists will work with the CSIR-IMTECH in Chandigarh, India, to develop new drug compounds against TB, and to devise safer, more effective oral treatment regimens against multidrug-resistant TB (MDR-TB). "TB remains a significant challenge in India, killing approximately half a million-people in 2015 alone," said Dr. Anil Koul, director, CSIR-IMTECH. "The partnership we have announced today with Johnson & Johnson has the potential to accelerate our work in support of India's National Strategic Plan, our accelerated action plan to End TB by 2025, and most importantly save lives." The partnership will combine CSIR-IMTECH’s expertise in ...

Original Article: J&J Partners with India's IMTECH to Develop New Treatments for TB


More From BioPortfolio on "J&J Partners with India's IMTECH to Develop New Treatments for TB"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...